Edgewise Therapeutics, Inc. reported its first quarter earnings, revealing a strong cash position of $532m and a net loss of $(28.5m). The company is advancing two clinical-stage programs, including a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback